BLUE
Bluebird bio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.
Market Cap: 159 Million
Primary Exchange: NASDAQ
Website: bluebirdbio.com
Shares Outstanding: 109 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.8056534118701602
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 1796 trading days
From: 2018-03-12 To: 2024-03-07
Lowest Point:
bluebird bio Breezes By For European Approval Of Its Gene Therapy Zynteglo
via: SeekingAlpha at 2019-06-11 14:08:42:000
bluebird bio ( BLUE ) announced that it had received European approval for its gene therapy Zynteglo to treat patients with beta-thalassemia. This was the first approval for the biotech which was an important milestone to reach. However, this is only the beginning. That's because bluebird bi… read more...
bluebird bio Breezes By For European Approval Of Its Gene Therapy Zynteglo
via: SeekingAlpha at 2019-06-11 14:08:42:000
bluebird bio ( BLUE ) announced that it had received European approval for its gene therapy Zynteglo to treat patients with beta-thalassemia. This was the first approval for the biotech which was an important milestone to reach. However, this is only the beginning. That's because bluebird bi… read more...
bluebird bio Breezes By For European Approval Of Its Gene Therapy Zynteglo
via: SeekingAlpha at 2019-06-11 14:08:42:000
bluebird bio ( BLUE ) announced that it had received European approval for its gene therapy Zynteglo to treat patients with beta-thalassemia. This was the first approval for the biotech which was an important milestone to reach. However, this is only the beginning. That's because bluebird bi… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|